Livogiva

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ingredjent attiv:

teriparatide

Disponibbli minn:

Theramex Ireland Limited

Kodiċi ATC:

H05AA02

INN (Isem Internazzjonali):

teriparatide

Grupp terapewtiku:

Calcium homeostasis

Żona terapewtika:

Osteoporosis

Indikazzjonijiet terapewtiċi:

Livogiva is indicated in adults.Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

Sommarju tal-prodott:

Revision: 1

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2020-08-27

Fuljett ta 'informazzjoni

20
B. PACKAGE LEAFLET
21
PACKAGE LEAFLET: INFORMATION FOR THE USER
LIVOGIVA 20 MICROGRAMS/80 MICROLITERS SOLUTION FOR INJECTION IN
PRE-FILLED PEN
teriparatide
This medicine is subject to additional monitoring. This will allow
quick identification of new
safety information. You can help by reporting any side effects you may
get. See the end of section 4
for how to report side effects.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Livogiva is and what it is used for
2.
What you need to know before you use Livogiva
3.
How to use Livogiva
4.
Possible side effects
5.
How to store Livogiva
6.
Contents of the pack and other information
1.
WHAT LIVOGIVA IS AND WHAT IT IS USED FOR
Livogiva contains the active substance teriparatide that is used to
make the bones stronger, and to
reduce the risk of fractures by stimulating bone formation.
Livogiva is used to treat osteoporosis in adults. Osteoporosis is a
disease that causes your bones to
become thin and fragile. This disease is especially common in women
after the menopause, but it can
also occur in men. Osteoporosis is also common in patients receiving
corticosteroids.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE LIVOGIVA
_ _
DO NOT USE LIVOGIVA
•
if you are allergic to teriparatide or any of the other ingredients of
this medicine (listed in
section 6).
•
if you suffer from high calcium levels (pre-existing hypercalcaemia).
•
if you suffer from serious kidney problems.
•
if you have ever been diagnosed with bone cancer or other cancers that
have spr

Karatteristiċi tal-prodott

1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
This medicinal product is subject to additional monitoring. This will
allow quick identification of
new safety information. Healthcare professionals are asked to report
any suspected adverse reactions.
See section 4.8 for how to report adverse reactions.
1.
NAME OF THE MEDICINAL PRODUCT
Livogiva 20 micrograms/80 microliters solution for injection in
pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 80 microliters contains 20 micrograms of teriparatide*.
Each pre-filled pen of 2.7 mL contains 675 micrograms of teriparatide
(corresponding to
250 micrograms per mL).
*Teriparatide, rhPTH(1-34), produced in
_P. fluorescens_
, using recombinant DNA technology, is
identical to the 34 N-terminal amino acid sequence of endogenous human
parathyroid hormone.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Colourless, clear solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Livogiva is indicated in adults.
Treatment of osteoporosis in postmenopausal women and in men at
increased risk of fracture (see
section 5.1). In postmenopausal women, a significant reduction in the
incidence of vertebral and non-
vertebral fractures but not hip fractures have been demonstrated.
Treatment of osteoporosis associated with sustained systemic
glucocorticoid therapy in women and
men at increased risk for fracture (see section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose of Livogiva is 20 micrograms administered once
daily.
The maximum total duration of treatment with Livogiva should be 24
months (see section 4.4).
The 24-month course of Livogiva should not be repeated over a
patient’s lifetime.
Patients should receive supplemental calcium and vitamin D supplements
if dietary intake is
inadequate.
Following cessation of Livogiva therapy, patients may be continued on
other osteoporosis therapies.
3
_Special populations _
_Elderly patients _
Dose adjustment based on age is not required